SS-31 (Elamipretide) in Australia: Mitochondrial Research Guide

SS-31 (also known as Elamipretide or MTP-131, sequence: D-Arg-Dmt-Lys-Phe-NH2) belongs to the Szeto-Schiller peptide class, developed by Hazel Szeto at Weill Cornell Medicine. Its key property is a 1,000–5,000 fold selective concentration in the inner mitochondrial membrane, driven by its alternating aromatic-cationic amino acid structure and affinity for the phospholipid cardiolipin.

Cardiolipin is uniquely present in the inner mitochondrial membrane and plays a critical structural role in organising the electron transport chain complexes into functional supercomplexes. In conditions of oxidative stress or ageing, cardiolipin is peroxidised and loses this organising function, impairing mitochondrial efficiency. SS-31 prevents cardiolipin peroxidation, preserving electron transport chain function.

• Heart failure, SS-31 reached Phase 2/3 clinical trials (PROGRESS-HFpEF) for heart failure with preserved ejection fraction, the most advanced clinical development of any mitochondria-targeted peptide
• Renal ischaemia-reperfusion injury, preclinical studies have demonstrated significant attenuation of acute kidney injury in ischaemia-reperfusion models, with improved renal function preservation
• Skeletal muscle ageing, research by Bhaskaran, Bhupinder, and colleagues has shown SS-31 administration in aged mice partially restores muscle mitochondrial function, exercise capacity, and reduced fatigue
• Neurodegeneration models, SS-31 has been investigated in models of Parkinson's disease and ALS, where mitochondrial dysfunction is a central pathological feature
• Diabetic complications, studies in models of diabetic nephropathy and cardiomyopathy have demonstrated protective effects attributable to preservation of mitochondrial structure and function

OzPeps stocks research-grade SS-31 with fast AU shipping. View SS-31 stock and pricing →

SS-31 is sold strictly for in-vitro laboratory research. Not TGA-approved. Not for human or animal consumption.